Drug
PF-06669571 clinical trials
Also written PF-06669571.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses PF-06669571 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related ApathyTerminatedPhase 2AbbVieNCT04958031Written as CVL-871 1.0 mg
- PF-06669571 In Subjects With Idiopathic Parkinson's DiseaseCompletedPhase 1PfizerNCT02565628Written as PF-06669571
- A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed ConditionsCompletedPhase 1PfizerNCT02184429Written as PF-06669571
Codes
What other systems call PF-06669571 · ClinicalTrials.gg INT000982
- MeSH (NLM) C000628211PF-06669571One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628211 | PF-06669571 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.